NEO logo

NeoGenomics (NEO) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

16 March 2004

Indexes:

Not included

Description:

NeoGenomics, Inc. is one of the leading companies in cancer diagnostics and pharmaceutical services, serving oncologists, pathologists, pharmaceutical companies, academic centers, and other specialists with innovative diagnostic and prognostic tests. The company was founded in 2002, with headquarters located in Fort Myers, Florida, USA. The clinical services segment provides cancer testing services for pathologists, oncologists, dermatologists, and other clinicians representing various communities, hospitals, and centers. The company is a leading provider of molecular sequencing and next-generation testing. The pharmaceutical services segment offers comprehensive testing services to support pharmaceutical clients' oncology programs from discovery to commercialization.

Events Calendar

Earnings

Next earnings date:

Feb 20, 2025

Recent quarterly earnings:

Nov 05, 2024

Recent annual earnings:

Feb 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 16, 2003

Analyst ratings

Recent major analysts updates

13 Dec '24 B of A Securities
Neutral
10 Dec '24 Jefferies
Buy
06 Nov '24 Needham
Buy
25 Sept '24 Needham
Buy
24 Sept '24 Benchmark
Buy
30 July '24 Stephens & Co.
Overweight
30 July '24 Needham
Buy
30 July '24 Benchmark
Buy
02 May '24 BTIG
Buy
01 May '24 TD Cowen
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NEO
zacks.com30 December 2024

NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO
globenewswire.com19 December 2024

TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the joint development agreement (the “Agreement” or “JDA”) with a North American battery cell manufacturer (“JDA Partner”) effective November 30, 2024. This collaboration aims to develop and enhance the performance of silicon anode materials for specialty electric automotive and mobility applications. There are no material terms or considerations as part of this JDA.

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NEO
businesswire.com11 December 2024

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.

NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO
globenewswire.com03 December 2024

TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, announces that Roberto Fia has resigned from the Company's Board of Directors effective November 29, 2024. NEO would like to thank him for his contributions to date.

NEO Battery Materials Confirms Stable and Unaffected Operations Amid South Korea's Declaration of Emergency Martial Law
NEO Battery Materials Confirms Stable and Unaffected Operations Amid South Korea's Declaration of Emergency Martial Law
NEO Battery Materials Confirms Stable and Unaffected Operations Amid South Korea's Declaration of Emergency Martial Law
NEO
globenewswire.com03 December 2024

TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, wishes to provide complete assurance and confirmation to its stakeholders that the recent declaration of emergency martial law in South Korea does not and will not impact the Company's operations and progress at its Research and Development (R&D) Scale-Up Centre located in the country. As of 1 AM KT, December 4, 2024, the South Korean National Assembly has passed a resolution to end the declaration of emergency martial law.

NEO Battery Materials to Develop High-Specification Silicon Anodes with OCSiAl Single Wall Carbon Nanotubes
NEO Battery Materials to Develop High-Specification Silicon Anodes with OCSiAl Single Wall Carbon Nanotubes
NEO Battery Materials to Develop High-Specification Silicon Anodes with OCSiAl Single Wall Carbon Nanotubes
NEO
globenewswire.com28 November 2024

TORONTO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the signing of a Memorandum of Understanding (“MOU”) with OCSiAl LLC (“OCSiAl”), the world's largest industrial producer of single wall carbon nanotubes (SWCNTs), on October 23, 2024. OCSiAl will supply NEO with SWCNT products to manufacture a high-specification model of NEO's polymer-coated silicon anodes. There are no material terms or considerations regarding this MOU.

NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments & Pathway to Commercialization
NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments & Pathway to Commercialization
NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments & Pathway to Commercialization
NEO
globenewswire.com25 November 2024

TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that the Company will be holding a corporate webinar on Thursday, December 5, 2024, at 7 PM EDT / 4 PM PDT / 9 AM KT.

NEO Battery Materials Appoints Prominent South Korean Attorney, Mr. Seok Hyung Lee, as New Director and Announces Battery Board Transition Initiative
NEO Battery Materials Appoints Prominent South Korean Attorney, Mr. Seok Hyung Lee, as New Director and Announces Battery Board Transition Initiative
NEO Battery Materials Appoints Prominent South Korean Attorney, Mr. Seok Hyung Lee, as New Director and Announces Battery Board Transition Initiative
NEO
globenewswire.com22 November 2024

TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the appointment of Mr. Seok Hyung Lee as a new independent director of the Company and the South Korean subsidiary, NBM Korea Co., Ltd. (“NBM Korea”), effective November 22, 2024.

NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
NEO
zacks.com06 November 2024

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NEO
seekingalpha.com05 November 2024

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Jeffrey Sherman - Chief Financial Officer Warren Stone - Chief Commercial Officer Kareem Saad - Head, Strategy and Transformation Andrew Lukowiak - Chief Innovation Officer Nate Montgomery - Vice President, Medical Services Melody Harris - Chief Operations Officer and President, Informatics Conference Call Participants Andrew Brackman - William Blair David Westenberg - Piper Sandler Mike Matson - Needham & Company Matthew Hewitt - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mark Massaro - BTIG Mason Carrico - Stephens, Inc. John Kim - Bank of America Andrew Cooper - Raymond James Puneet Souda - SVB Leerink Operator Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

FAQ

  • What is the primary business of NeoGenomics?
  • What is the ticker symbol for NeoGenomics?
  • Does NeoGenomics pay dividends?
  • What sector is NeoGenomics in?
  • What industry is NeoGenomics in?
  • What country is NeoGenomics based in?
  • When did NeoGenomics go public?
  • Is NeoGenomics in the S&P 500?
  • Is NeoGenomics in the NASDAQ 100?
  • Is NeoGenomics in the Dow Jones?
  • When was NeoGenomics's last earnings report?
  • When does NeoGenomics report earnings?
  • Should I buy NeoGenomics stock now?

What is the primary business of NeoGenomics?

NeoGenomics, Inc. is one of the leading companies in cancer diagnostics and pharmaceutical services, serving oncologists, pathologists, pharmaceutical companies, academic centers, and other specialists with innovative diagnostic and prognostic tests. The company was founded in 2002, with headquarters located in Fort Myers, Florida, USA. The clinical services segment provides cancer testing services for pathologists, oncologists, dermatologists, and other clinicians representing various communities, hospitals, and centers. The company is a leading provider of molecular sequencing and next-generation testing. The pharmaceutical services segment offers comprehensive testing services to support pharmaceutical clients' oncology programs from discovery to commercialization.

What is the ticker symbol for NeoGenomics?

The ticker symbol for NeoGenomics is NASDAQ:NEO

Does NeoGenomics pay dividends?

No, NeoGenomics does not pay dividends

What sector is NeoGenomics in?

NeoGenomics is in the Healthcare sector

What industry is NeoGenomics in?

NeoGenomics is in the Diagnostics & Research industry

What country is NeoGenomics based in?

NeoGenomics is headquartered in United States

When did NeoGenomics go public?

NeoGenomics's initial public offering (IPO) was on 16 March 2004

Is NeoGenomics in the S&P 500?

No, NeoGenomics is not included in the S&P 500 index

Is NeoGenomics in the NASDAQ 100?

No, NeoGenomics is not included in the NASDAQ 100 index

Is NeoGenomics in the Dow Jones?

No, NeoGenomics is not included in the Dow Jones index

When was NeoGenomics's last earnings report?

NeoGenomics's most recent earnings report was on 5 November 2024

When does NeoGenomics report earnings?

The next expected earnings date for NeoGenomics is 20 February 2025

Should I buy NeoGenomics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions